NDATOPICALSHAMPOO
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPITROL (chloroxine) is a topical antimicrobial shampoo approved in 1976 for the treatment of seborrheic dermatitis and other scalp conditions. The product works through chloroxine's antimicrobial mechanism to reduce scalp inflammation and associated symptoms. It represents a legacy dermatological treatment with a well-established safety profile in the topical antifungal/antibacterial space.
LOE Approaching
Brand faces moderate competitive pressure (30% intensity) with LOE approaching, signaling potential team consolidation and shift toward legacy product management or divestiture strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CAPITROL presents a limited career trajectory as a legacy topical product with zero active job postings and approaching LOE. Career growth on this brand is constrained; roles focus on maintenance, price management, and managed care defense rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on CAPITROL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.